Resultados: 4

    Guidelines on long-acting injectable cabotegravir for HIV prevention

    In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing...

    Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact

    As the HIV response moves to focusing on closing the remaining gaps in prevention, testing and treatment services, an evolution in the underlying routine data systems is needed to identify epidemiologic patterns and service gaps, and accelerate focused interventions. These guidelines focus on the collec...

    Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV

    Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa. These guidelines update the recommendations that were first released in 2018 ...

    WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia 

    The leishmaniases are a group of diseases caused by Leishmania spp., which occur in cutaneous, mucocutaneous and visceral forms. They are neglected tropical diseases (NTDs), which disproportionately affect marginalized populations who have limited access to health care. HIV co-infected patients with Leis...